Abstract
The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.
| Original language | English |
|---|---|
| Pages (from-to) | 423-429 |
| Number of pages | 7 |
| Journal | Diabetes and Metabolism Journal |
| Volume | 41 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2017 Dec 1 |
Bibliographical note
Publisher Copyright:© 2017 Korean Diabetes Association.
All Science Journal Classification (ASJC) codes
- Endocrinology, Diabetes and Metabolism
